AMAG Pharmaceuticals, Inc. (AMAG) Stake Decreased by OxFORD Asset Management LLP

OxFORD Asset Management LLP cut its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 28.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 143,107 shares of the specialty pharmaceutical company’s stock after selling 56,761 shares during the period. OxFORD Asset Management LLP owned 0.41% of AMAG Pharmaceuticals worth $2,633,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in AMAG. BlackRock Inc. increased its stake in shares of AMAG Pharmaceuticals by 67,790.9% during the 1st quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after purchasing an additional 4,988,054 shares during the last quarter. State Street Corp increased its stake in shares of AMAG Pharmaceuticals by 75.2% during the 1st quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock worth $56,876,000 after purchasing an additional 1,082,366 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of AMAG Pharmaceuticals by 152.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock worth $23,129,000 after purchasing an additional 619,370 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of AMAG Pharmaceuticals by 2,768.3% during the 1st quarter. Perceptive Advisors LLC now owns 560,000 shares of the specialty pharmaceutical company’s stock worth $12,628,000 after purchasing an additional 540,476 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of AMAG Pharmaceuticals by 162.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 607,980 shares of the specialty pharmaceutical company’s stock worth $13,710,000 after purchasing an additional 376,139 shares during the last quarter.

Several research firms have recently weighed in on AMAG. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Citigroup Inc. lowered their price objective on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a research note on Friday, July 7th. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Deutsche Bank AG set a $24.00 price objective on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, July 7th. Finally, BidaskClub lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and four have issued a buy rating to the company. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $27.67.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 18.95 on Thursday. The company has a 50-day moving average of $18.31 and a 200-day moving average of $19.44. AMAG Pharmaceuticals, Inc. has a 52 week low of $16.00 and a 52 week high of $36.83. The firm’s market cap is $668.71 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business had revenue of $158.39 million during the quarter, compared to the consensus estimate of $158.83 million. During the same quarter last year, the company posted $1.45 earnings per share. The firm’s quarterly revenue was up 24.3% compared to the same quarter last year. Equities research analysts forecast that AMAG Pharmaceuticals, Inc. will post ($1.38) earnings per share for the current fiscal year.

In related news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the sale, the senior vice president now owns 28,336 shares in the company, valued at $566,720. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “AMAG Pharmaceuticals, Inc. (AMAG) Stake Decreased by OxFORD Asset Management LLP” was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2017/10/05/amag-pharmaceuticals-inc-amag-stake-decreased-by-oxford-asset-management-llp.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply